Pagina 5 - I migliori ematologo-oncologi di Ematologia Oncologia - TOP-171medici

Dr. Mustafa Emiroglu is a general surgery specialist at Memorial Bodrum Hospital. He has significant experience from his work at Sağlık Bilimleri University Tepecik SUAM (2016–2023) and Kırşehir Hospital (1997–1999).

He earned his medical degree from Istanbul University Cerrahpaşa Faculty of Medicine. He completed his specialization at Tepecik Training and Research Hospital. Dr. Emiroglu is a member of the Turkish Society of Surgery, the Endocrine Surgery Association, and the Colorectal Surgery Association.

He has attended advanced courses, including the Europe Senology Academia. He has also received training in proctologic, hemorrhoidal, and oncoplastic breast surgery, as well as thyroid diseases.

2002 – 2008 – Siriraj Medical School, Mahidol University

2008 – 2013 – Department of Internal Medicine, Rajavithi Hospital

2013 – 2015 – Department of Cardiology, Internal Medicine Rajavithi Hospital

2019 – 2020 – Cardiology Intervention, Department of Cardiology, Internal Medicine Rajavithi Hospital

Languages: English and Thai

Education and Training

Doctor of Medicine, Cum Laude, University of Navarra (1991)

Medical Degree, University of Navarra (1979–1985), Graduated with Honors

Board-Certified Specialist in Medical Oncology, via Spanish MIR system, Clínica Universidad de Navarra (1986–1989)

Advanced Fellowship in Immunotherapy, Cleveland Clinic Foundation, USA

Professional Experience

Head of Medical Oncology (1993–2000) and Director of the Cancer Institute (2000–2002), General Hospital of Catalonia

Director of Hematopoietic Progenitor Transplant Program, General Hospital of Catalonia (1993–2002), accredited by the Catalonian Health Department

Senior Specialist in Oncology, Quirónsalud Torrevieja (since 2002)

Clinical Innovations & Special Programs

Personalized Cancer Therapy using RNA microarrays and pharmacogenomics

Autologous Bone Marrow Transplants and High-Dose Chemotherapy

High-Dose Interleukin-2 Therapy via intravenous bolus for solid tumors

Personalized Cellular Anti-Tumor Vaccines

Hyperthermic Isolated Limb Perfusion with TNF and melphalan

Intra-arterial and Intraoperative Chemotherapy (HIPEC) for advanced cancers

Research & Academic Contributions

Author of 120+ scientific papers and conference presentations

Active contributor to the development of novel cancer immunotherapies and drug personalization strategies

Memberships

AACR – American Association for Cancer Research

ASCO – American Society of Clinical Oncology

ASH – American Society of Hematology

Education and Expertise

• DOKUZ EYLÜL UNIVERSITY FACULTY OF MEDICINE

Experience

• ULUDAĞ UNIVERSITY – FACULTY OF MEDICINE, INTERNAL MEDICINE
• DOKUZ EYLÜL UNIVERSITY – FACULTY OF MEDICINE, INTERNAL MEDICINE-HEMATOLOGY
•  
• Interests:
•  
• Joint Swelling

Diverticular Bowel Disease (Diverticulosis)

Hydronephrosis (Kidney Swelling)

Bad Taste in Mouth

Blood in Urine (Hematuria)

Liver Abscess

Fat Metabolism Disorders

Osteomalacia (Bone Softening)

Hormone Excess

Glomerular Diseases (Nephritis, Nephrotic Syndrome)

Univ.-Prof. Dr. Heinz Gisslinger is a leading hematologist and internal oncologist at the Medical University of Vienna and the Confraternität Private Clinic Josefstadt. He helped found the Laboratory for Myeloproliferative Neoplasms. He is Program Director for Myeloproliferative Neoplasms and leads clinical and translational research.

He pioneered interferon therapy for myeloproliferative neoplasms (MPNs). He first used it clinically in the 1980s and has advanced it for more than four decades. His expertise includes polycythemia vera, essential thrombocythemia, primary myelofibrosis, chronic myeloid leukemia, and multiple myeloma.

Prof. Elad Jacoby, MD, heads the Pediatric Cell Therapy Center at Sheba Medical Center. He is the Medical Director of the Advanced Biotherapy Center. He is a pioneer of pediatric CAR T‑cell therapy in Israel. He led one of the first national leukemia programs. He has almost 20 years of clinical and research experience.

He specializes in CAR T‑cell therapy, bone marrow and stem cell transplantation, and high‑risk pediatric leukemias and lymphomas. He leads international clinical trials and has authored over 240 publications. His collaborations include Johns Hopkins Hospital and the U.S. National Cancer Institute. He is an Associate Professor at Tel Aviv University. He received his MD from Tel Aviv University, completed residency at Sheba Medical Center, and fellowships at Johns Hopkins and the National Cancer Institute. He is board‑certified in Pediatrics and in Pediatric Hematology and Oncology. He serves on the IBFM CAR T‑Cell Taskforce and the Sheba Institutional Review Board. He leads the integration of CAR T‑cell therapy with transplantation.

Il medico dirige la Divisione di Ematologia-Oncologia e si è laureato presso il College of Medicine dell'Università Nazionale di Seoul.<\/p>

È specializzato in cancro ai polmoni, cancro alla testa e al collo e cancro esofageo. È membro di diverse organizzazioni prestigiose, tra cui l'Associazione Medica Coreana, l'American Society of Clinical Oncology e l'European Society of Medical Oncology.<\/p>

Il medico è specializzato in linfomi e leucemia linfatica cronica, guidando innovazioni nell'analisi e nel trattamento delle malattie ematologiche. Rinomato a livello globale per la sua esperienza nella Leucemia Linfatica Cronica (CLL), il medico conduce ricerche cliniche e di base significative, concentrandosi sulla patogenesi molecolare e nuovi approcci terapeutici.<\/p>

Attualmente coinvolto in oltre 80 studi dalla fase 1 alla fase 3, il medico contribuisce allo sviluppo di nuovi farmaci e trattamenti. Come Capo dell'Ematologia presso l'IOB Institute of Oncology e Capo del Dipartimento di Ematologia presso il Vall d’Hebron University Hospital, il medico ha pubblicato oltre 100 articoli su riviste prestigiose.<\/p>

Il medico è specializzato in ematologia con un focus sul trattamento dei linfomi. Con una vasta esperienza in questo campo, il medico ha contribuito in modo significativo ai progressi nel trattamento dei linfomi e nella cura dei pazienti. Il medico è riconosciuto per la sua esperienza e impegno nel migliorare i risultati per i pazienti con disturbi ematologici.<\/p>